Relation of maternal vitamin D status with gestational diabetes mellitus and perinatal outcome by Mutlu, N et al.
Relation of  maternal vitamin D status with gestational diabetes 
mellitus and perinatal outcome
Niyazoglu  Mutlu1, Hatipoglu Esra1,  Aydogan  Begum2,  Dellal  Fatma3, 
Yavuz  Arzu4,  Hacioglu Yalcin5,  Kaya  Fatih5,  Kumru Selahattin6
1.  Division of  Endocrinology and Metabolism, Department of  Internal Medicine, Cerrahpasa Medical School, 
     Istanbul University,  Istanbul, Turkey
2.  Department of  Obstetrics and Gynecology, Cerrahpasa Medical School, Istanbul University, Istanbul, Turkey
3.  Department of  Endocrinology and Metabolism, Ministry of  Health’s Ankara Ataturk Education and Research 
     Hospital, Ankara, Turkey
4.  Department of  Obstetrics and Gynecology, Ministry of  Health’s Kocaeli Derince Education and Research 
     Hospital, Kocaeli, Turkey
5.  Department of  Internal Medicine, Ministry of  Health’s Istanbul Education and Research Hospital, Istanbul, 
    Turkey
6.  Department of  Obstetrics and Gynecology, Ministry of  Health’s Antalya Education and Research Hospital, 
    Antalya, Turkey
Abstract
Objective: To investigate the relationship between maternal vitamin D status and glucose intolerance, and its impact on 
pregnant women and their newborns.
Methods: A cohort of  pregnant women were divided into three groups: women with gestational diabetes mellitus, ones 
with normal results both after the 50 gr and 100 gr OGTT (CG-1) and ones  having a positive result after the 50 gr OGTT 
screening but negative results for gestational diabetes mellitus (GDM) after the 100 gr OGTT (CG-2) 
Results: The newborn length in CG-1 was greater than in GDM and CG-2 (p= 0.002 and p= 0.02). Fasting blood glucose 
and insulin resistance (IR) were negatively correlated with length of  the newborns (r=-0.3, p=0.03 and r=-0.3, p=0.01). The 
newborns of  women with GDM had lower APGAR-1 and 5 scores than those of  CG-1 and CG-2 (APGAR-1 p= 0.001 and 
p= 0.004, APGAR-5 p=0.005 and p=0.007, respectively). APGAR scores were correlated negatively with IR (APGAR-1 r=-
0.32, p=0.01, APGAR-5 r=-0.3, p=0.03) and positively with 25OHD levels (APGAR-1  r=0.3, p=0.01, APGAR-5  r=0.3, 
p=0.02).
Conclusion: Vitamin D deficiency, gestational diabetes and insulin resistance are interrelated. Severe vitamin D deficiency 
during pregnancy is associated with poor pregnancy and neonatal outcome.
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Introduction
Vitamin D deficiency is common all around the world 
and has a prevalence of  26-98% in pregnancy, bringing 
concerns about its consequences and need for supple-
mentation1-4. As vitamin D receptor is expressed widely 
in nucleated cells, it does not only have a role in calcium 
and bone homeostasis but also in various organs and 
system functions. 
Vitamin D has a wide spectrum of  extraskeletal effects 
and its deficiency has various consequences includ-
ing muscle weakness, impairment of  immune system, 
increase in cardiovascular disease and hypertension, 
disturbance of  neuropsychiatric function and even in-
creased mortality5-8. Taking this wide range of  actions 
into consideration, it is not surprising that Vitamin D 
also has a role in insulin homeostasis and resistance. 
It may improve beta-cell activity and increase insulin 
            523African Health Sciences Vol 15 Issue 2, June 2015
sensitivity9. Poor Vitamin D status has also been linked 
with type-2 diabetes, obesity and other elements of  
metabolic syndrome10,11. 
Pregnancy is another condition associated with insulin 
resistance and hyperinsulinemia. During pregnancy, the 
effects of  diabetogenic hormones cannot be handled in 
women with insufficient pancreatic reserve, thus ges-
tational diabetes occurs. Gestational diabetes is an im-
portant health issue since it has serious consequences 
involving increased risks of  preeclampsia, macrosomia, 
cesarean delivery, and their associated morbidities. 
There have been several reports that tried to ascertain 
the link between diabetes in pregnancy and maternal 
vitamin D status. To date, the connection between vi-
tamin D status and gestational diabetes mellitus and/
or insulin resistance is not clear.  Given what is known 
in existing literature, the current study aimed to investi-
gate the relationship between maternal vitamin D status 
with glucose intolerance and its consequences in preg-
nant women. 
Materials and methods
A total of  21 consecutive women with gestational dia-
betes mellitus (GDM) were included in the study. Age 
and body mass index-matched 43 healthy pregnant sub-
jects constituted the control group. There were no ra-
cial/ethnic or socioeconomic differences between the 
groups.
The method used for diagnosing gestational diabetes 
had two parts. First, a 50 gr oral glucose tolerance test 
(OGTT) for screening was performed at 24 to 28 weeks 
of  gestation. Plasma glucose, measured one hour later, 
was considered elevated if  it was ≥ 7.8 mmol/L (140 
mg/dL). Those with elevated levels were further evalu-
ated with a 100 gr three-hour OGTT after a three-day 
120 kcal/day carbohydrate-containing diet and 8 hours 
of  fasting. GDM was diagnosed with at least two ab-
normal results during 100 gr OGTT: plasma glucose 
during fasting ≥ 5.8 mmol/L (105 mg/dL) or at one 
hour ≥ 10.5 mmol/L (190 mg/dL) or at two hour ≥ 
9.2 mmol/L (165 mg/dL) or at three hour ≥ 8 mmol/L 
(145 mg/dL)12. Of  the 21 cases with GDM, 6 (29%) 
were on the diet only whereas 15 (71%) cases were on 
insulin therapy.
The control group was further stratified by their OGTT 
results. Women with normal results after both the 50 gr 
and 100 gr OGTT comprised control group-1 (CG-1) 
whereas those with elevated glucose levels after the 50 
gr OGTT but normal levels after the 100 gr OGTT 
constituted control group-2 (CG-2).
Demographic features and a medical history which in-
cluded number of  pregnancies, parity and abortus were 
obtained from all subjects. Height and weight were 
used to calculate the body mass index (BMI). Gesta-
tional week at birth, fetal status, weight and length of  
the newborn, and APGAR scores were also included. 
Newborns with weight below the 10th percentile for 
gestational age were considered small for gestational 
age (SGA) whereas newborns with birth weight greater 
than the 90th percentile for age were considered large 
for gestational age13. APGAR scores were evaluated at 
one and five minutes (APGAR-1 and 5) of  age based 
on heart rate, respiratory effort, muscle tone, reflex irri-
tability and color of  the newborn14. 
Fasting blood glucose (FBG), calcium (Ca), parathyroid 
hormone (PTH) and 25OHD levels of  the cases were 
evaluated from their out-patient clinic registries when 
the 50 gr-OGTT was performed. Laboratory results 
were obtained during the study period and were con-
current with physical examination.  Insulin resistance 
(IR) was calculated by the homeostasis model of  as-
sessment (HOMA) according to fasting blood glucose 
and insulin levels15. Cases with HOMA-IR >2.5 were 
considered to have insulin resistance16. 
The study protocol was approved by the ethics com-
mittee of  the Ministry of  Health’s antalya education 
and research hospital (26 December 2011/146). All the 
subjects read and signed the informed consent forms 
before enrolling in the study.
The data was statistically analyzed with the SPSS 15.0 
package program. Chi-square test was used for categor-
ical variables.  Kruskal-Wallis test was used to compare 
the three groups.  The variables with significance were 
then evaluated by Mann-Whitney U test to investigate 
difference between the groups. Independent varia-
bles affecting HOMA-IR, APGAR score and neonatal 
length were explored with multiple regression analysis. 
Spearman’s correlation coefficient was used for the cal-
culation of  associations between variables. p <0.05 was 
considered as statistically significant.
Results
The mean age of  the patients with GDM was 32.9 ± 
4.7 years; it was 29.3 ± 4  in CG-1 cases and 30.9 ± 
5.5 years in CG-2 cases (p = 0.09).The mean BMI of  
patients with GDM and  in CG-1 and CG-2 cases were 
27.2±4.9, 25.2±4.6 and 24.9±4.5 kg/m2, respectively 
(p=0.22).
Median numbers of  pregnancy in GDM, CG-1 and 
CG-2 were 2.5 [IQR: 2-3.75], 2 [IQR: 1-3] and 2 [IQR: 
1-2], respectively (p=0.1). Median numbers of  parity in 
GDM, CG-1 and CG-2 were 1 [IQR: 1-2], 1 [IQR: 0-2] 
and 0 [IQR: 0-1.5], respectively (p=0.2). The incidence 
of   abortus was 0 [IQR: 0-1] in the GDM group,  0 
[IQR: 0-0] in CG-1 and  0 [IQR: 0-1] in CG-2 (p=0.4). 
Median gestational week at birth was 38 [IQR: 36-38] 
weeks in GDM group, 38 [IQR: 37-40]  in CG-1 and 38 
[IQR: 38-39]  in CG-2 (p=0.3). The mode of  delivery 
and complications pertaining to the current pregnancy 
during the study period and the median birth weight, 
length and APGAR scores of  the newborns in each 
group are summarized in (Table I). 
 
 
Table 1. Mode of delivery, complications and fetal status in each group 
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9 [9-9] 9 [8-9]    0.006* 
 
C /S cesarean section, IUGR intrauterine growth retardation, TTN transient tachypnea of 
newborn, SGA small for gestational age, LGA large for gestational age †The results are 
presented as median and interquartile range [IQR]  
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There was a tendency towards a difference between the 
three groups in terms of  presence of  preterm labor, 
although the difference was not statistically significant 
(p=0.06). The newborn length in CG-1 was higher 
than in GDM and CG-2 (p= 0.002 and p= 0.02, re-
spectively). There was no difference between GDM 
and CG-2 in terms of  median newborn length (p= 0.3). 
The newborns of  the GDM group recorded lower of  
APGAR-1 and 5 scores than the newborns of  CG-1 
and CG-2 (for APGAR-1 p= 0.001 and p= 0.004, for 
APGAR-5 p=0.005 and p=0.007, respectively). The 
median scores of  APGAR-1 and 5 were not different 
between the newborns of  CG-1 and CG-2 (p=0.5 and 
p=0.9, respectively).
FBG levels were higher in cases with GDM than in 
CG-1 and CG-2 (p< 0.001 and p=0.004). Cases with 
higher glucose levels after the 50 gr OGTT (CG-2) also 
had higher FBG levels than the cases that had normal 
glucose levels after the 50 gr OGTT (CG-1) (p=0.001). 
HOMA-IR was significantly higher in patients with 
GDM compared to the cases in CG-1 (p=0.01). Cases 
in CG-2 did not have significantly different levels of  
HOMA-IR than the patients with GDM and the cas-
es in CG-1 (p=0.2 and p=0.1, respectively) (Table II). 
25OHD levels were not different between the three 
groups (p=0.6).
 
Table 2. Comparison of HOMA-IR and laboratory values between the three groups 
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34   
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34.6     
[30.5-43.9] 









When the whole cohort was taken into consideration, 
FBG was positively correlated with age of  the cases 
(r=0.3, p=0.02, n=60), BMI (r=0.4, p=0.001, n=61), 
HOMA-IR (r=0.5, p< 0.001, n=62), and was nega-
tively correlated with length of  the newborns (r=-0.3, 
p=0.03, n=62) (Figure 1).  HOMA-IR was positively 
correlated with BMI (r=0.3, p=0.02, n=63) whereas it 
was negatively correlated with length of  the newborns 
(r=-0.3, p=0.01, n=64), APGAR- 1 (r=-0.32, p=0.01, 
n=62) and APGAR-5 (r=-0.3, p=0.03, n=62) (Figure 1 
and Figure 2).
In addition, there was a negative correlation between 
HOMA-IR and Ca levels (r=-0.3, p=0.02, n=64). 
25OHD levels were also negatively correlated with 
HOMA-IR and BMI (r=-0.5, p< 0.001, n=64 and r=-
0.3, p=0.04, n= 63, respectively) (Figure 3). 
Figure 1
Figure 2
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Maternal levels of  25OHD showed a positive correla-
tion with APGAR-1 and APGAR-5 scores of  the new-
borns (r=0.3, p=0.01, n=62 and r=0.3, p=0.02, n=62) 
(Figure 2).   
Multiple regression analysis was used to test if  BMI, 
252Dvit levels and FBG predicted HOMA-IR, AP-
GAR score and neonatal length.  In the regression anal-
ysis for HOMA-IR (adjustedR2= 0.20, F(3,57)=4.71, 
p=0.005), it was found that 25OHDvit levels signifi-
cantly predicted HOMA-IR (β=-0.3, p=0.02). In the re-
gression analysis for APGAR score (adjustedR2= 0.10, 
F(3,55)=3.2, p=0.03) APGAR-1 was associated with 
FBG (β=-0.35, p=0.01).  Neonatal length was also as-
sociated with FBG (β=-0.35,p=0.01, adjustedR2= 0.09, 
F(3,57)=3.012, p=0.03).
Of  the cases in GDM group 16 (76%), in CG-1 7(47%) 
and in CG-2  17 (61%) had severe vitamin D deficiency 
(25OHDvit levels below 10 ug/l) (p=0.2). When the 
entire cohort was stratified by levels of  25OHDvit, 
with a cut-off  10 ug/l, those with levels below 10 ug/l 
(n=40) had increased HOMAIR compared to the cases 
who had higher 25OHDvit levels (n=24) ( 2.4 [IQR: 
1.5-3.5] and 1.6 [IQR: 1.1-2.1],  respectively, p=0.02). 
Both APGAR-1 and 5 scores of  the newborns were 
lower in case of  decreased maternal 25OHDvit.  AP-
GAR-1 scores of  the newborns with maternal lev-
els below and above 10 ug/l were 7 [IQR: 7-8] and 8 
[IQR: 8-8], respectively (p=0.001).  APGAR-5 scores 
of  the newborns were 8 [IQR: 8-9] in those with ma-
ternal 25OHDvit levels below 10 ug/l and 9 [IQR: 9-9] 
in those with maternal 25OHDvit levels above 10 ug/l 
(p=0.002). Number of  cases who had preterm labor 
were higher in women with 25OHDvit levels below 10 
ug/l than the women with higher levels (n=12 (30%) 
and n=2 (8%), respectively, p=0.04). Also preeclampsia 
was seen more frequently in cases with lower 25OHD-
vit levels in comparison to the cases with levels above 10 
ug/l (n=7 (18%) and n=0 (0%), respectively, p=0.03). 
Discussion
The current study shows that low vitamin D levels are 
associated with increased maternal insulin resistance 
and body mass index. Decrease in maternal vitamin 
D levels is also correlated with lower APGAR scores 
of  the newborn. Severe vitamin D deficiency was also 
associated with increased frequency of  preterm labor 
and preeclampsia. Additionally, increased maternal fast-
ing blood glucose, presence of  gestational diabetes and 
insulin resistance contributed to lower APGAR scores. 
These results indicate that metabolic condition of  the 
mother is closely associated with health of  the new-
born and vitamin D deficiency not only contributes to 
metabolic impairment in the mother but also is related 
with birth related complications and poor health of  the 
newborn. Both fasting blood glucose and insulin resist-
ance had a negative impact on length of  the newborn. 
Women with gestational diabetes also tended to have 
preterm labor more frequently than the women with-
out diabetes, although the difference was not statistical-
ly significant. 
GDM is the onset or first recognition of  impaired glu-
cose tolerance during pregnancy17. Since insulin resist-
ance is a major contributing factor for GDM, in the 
present study, as expected, HOMA-IR was found to be 
significantly higher in cases with GDM. There are sev-
eral well-known risk factors for developing GDM, in-
cluding increased maternal age and body mass index18. 
In the current study FBG increased with advanced age. 
Women with GDM tended to be older, but this was not 
statistically significant. 
GDM has various adverse outcomes which tend to in-
crease with higher maternal FBG levels and these out-
comes also influence the newborn19-21. Rates of  preterm 
labor increase when pre-gestational diabetes is present 
22. Likewise, in the present study, women with GDM 
tended to have higher incidences of  preterm labor, but 
did not reach a statistically significant level of  associa-
tion. In addition, newborns of  the women with GDM 
had lower scores of  APGAR in comparison to new-
borns of  women without diabetes. Nevertheless, the 
median scores were at levels calling for urgent medical 
attention. Moreover, increased levels of  maternal FBG 
and insulin resistance were associated with lower AP-
GAR scores. Since APGAR reflects general well-being 
of  the newborn, these results suggest that maternal 
glucose metabolism may influence health status of  the 
newborn.
Interestingly, the median length of  the newborns of  
women without diabetes was significantly higher than 
those of  women with positive results only after the 
50 gr OGTT and GDM. The reason why infants of  
women with diabetes had lower length is inconclusive. 
However, in the whole cohort, both maternal FBG and 
HOMA-IR were negatively correlated with length of  
the newborns. In regression analysis FBG was a reli-
able predictive factor for decreased newborn length. 
Impaired maternal glucose metabolism and insulin re-
sistance may be seen as contributing factors. Previous 
reports indicate that 10-20% of  the infants of  mothers 
with diabetes have hypocalcemia and this proportion 
may reach up to 50%23. 
In our study, maternal HOMA-IR was negatively cor-
related with maternal Ca levels. Thus, increase in in-
sulin resistance was also associated with a decrease in 
Ca levels. Theoretically, maternal serum Ca levels may 
have some impact on fetal bone maturation and fetal 
growth. Accordingly, increased glucose levels and insu-
lin resistance in pregnant women may have indirectly 
affected length of  the newborns. Although statistically 
insignificant, lower levels of  25OHD in women with 
GDM may be responsible for lower newborn length in 
the present study since vitamin D inadequacy may alter 
fetal skeletal development24,25. However, further studies 
are necessary for a certain explanation.
The relationship between Vitamin D deficiency and 
GDM is controversial. While a number of  previous 
studies have found an association between decreased 
levels of  25OHD and GDM, others have failed to show 
such an association26-30. In the current study, 25OHD 
levels were 36.7% and 28% lower in the groups of  
GDM and CG-2, respectively. However, this decrease 
was not statistically significant. A distinctive character-
istic and one of  the limitations of  our study was the 
overwhelmingly lower levels 25OHD than found in 
previous studies. Ethnicity may be a major contributing 
factor since 25OHD levels may vary between different 
ethnic groups27,29. All cases in our cohort were of  the 
same ethnic origin. In the whole cohort, lower levels 
of  25OHD were associated with higher HOMA-IR 
and increased BMI, suggesting vitamin D deficiency 
during pregnancy may be related to the components 
of  metabolic syndrome, namely insulin resistance and 
higher BMI. Also in regression analysis vitamin D levels 
were predictive of  insulin resistance. Additionally, both 
human and animal studies show maternal Vitamin D 
deficiency also has adverse perinatal outcomes31,32. Al-
though the exact mechanism has not been found, in the 
light of  this data, it was not surprising that in our study, 
lower levels of  25OHD were associated with lower AP-
GAR scores.
Figure 3
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Most striking examples for impact of  low maternal vi-
tamin D levels on maternal and fetal outcomes were 
revealed when the whole cohort was grouped based on 
presence and absence of  severe vitamin D deficiency, 
with a cut-off  of  10 ug/l. Severe vitamin D deficien-
cy was associated with maternal insulin resistance, in-
creased frequencies of  preterm labor and preeclampsia, 
and with decreased APGAR scores of  the newborns. 
This means extra caution both for the mother and the 
newborn should be taken when physicians deal with 
pregnancies especially in the presence of  severe vitamin 
D deficiency.
Limitations
This study was not without certain limitations. First 
the method for screenin GDM is still controversial. Al-
though certain organizations recommend one step apr-
roach with 75-gram OGTT others recommend two step 
approach or any of  them15,33-36. With one step approach 
more women are labeled with GDM and it is uncertain 
whether there will be any benefit from treating them all, 
rendering this approach not cost effective.15 Therefore 
we preferred to use the two-step approach. Moreover in 
addition to extremely low levels of  25OHD, other limi-
tations include the measurement of  the levels once dur-
ing whole pregnancy and uncertainty of  the contribut-
ing factors to the low levels including diet, lifestyle and 
medications. Further studies are needed to demonstrate 
the relation between maternal serum 25OHD concen-
tration and fetal development and perinatal outcome. 
Conclusion
Lower maternal serum vitamin D is related with both 
maternal insulin resistance and adverse perinatal out-
comes of  newborns. Particularly severe vitamin D defi-
ciency during pregnancy may have detrimental effects. 
Infants of  the women with vitamin D deficiency and/
or gestational diabetes mellitus should be carefully eval-
uated. During pregnancy, insulin resistance and vitamin 
D status are interrelated, so while dealing with one of  
them the other should also be taken into consideration. 
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